Clinical Trials Browser

Phase 1/2 × erdafitinib × 30 days × Clear all

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

Non-Muscle Invasive Bladder Neoplasms